Protracted high-dose interferon gamma therapy for chronic experimental nephropathy

F. Ginevri, E. Bergamaschi, A. Mutti, A. Trivelli, G. Salvidio, G. Fabbretti, F. Perfumo, G. M. Ghiggeri

Research output: Contribution to journalArticlepeer-review


This study focused on the utility of interferon gamma (IFN gamma) as an anti-fibrotic drug in renal experimental fibrosis; the nephropathy was induced by two doses of Adriamycin (ADR) in 20 Sprague Dawley rats, 10 of which were randomly assigned to receive IFN gamma (45,000 UI) on alternate day for 16 weeks. At the end of the follow up, ADR rats treated with IFN gamma developed massive proteinuria, slight renal insufficiency, and presented diffuse glomerulosclerosis, tubulo interstitial infiltration and fibrosis. No difference was found in the composition of tubulo-interstitial infiltrates, mainly consisting in CD4+T lymphocytes with a minor component of CD8+T cells, in comparison with rats treated with ADR alone. These observations demonstrate the inefficacy of a protracted high-dose treatment with IFN gamma in chronic experimental nephropathy with interstitial fibrosis.

Original languageEnglish
JournalLife Sciences
Issue number4
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Protracted high-dose interferon gamma therapy for chronic experimental nephropathy'. Together they form a unique fingerprint.

Cite this